• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. May 1983; 71(5): 1336–1341.
PMCID: PMC436996

Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen.

Abstract

The contribution of fibrin stabilization to clot strength, measured as the static elastic modulus, was evaluated in human plasma by two independent procedures. In the first approach, amine inhibitors of fibrin stabilization were examined for their effects on the rigidity of normal plasma clots. It is a unique property of these inhibitors that they do not interfere with the reversible aggregation of fibrin molecules, i.e., do not delay clotting time, but selectively prevent only the formation of gamma-glutamyl-epsilon-lysine protein-to-protein linkages. Though the compounds tested were of different chemical structures and potencies, a fivefold reduction in clot strength was obtained in each instance. This value of 20% of normal seems to correspond to the rigidity of the Factor XIII-deficient plasma clot because, as demonstrated by the second approach, when a plasma specimen that genetically lacked the fibrin stabilizing factor was supplemented by the addition of measured amounts of the purified zymogen, a fivefold increase in clot strength could be achieved. The described procedure of evaluating Factor XIII in terms of correcting the elastic modulus of a deficient plasma clot is considered an important assay for the functional competence of purified preparations of the zymogen for the purpose of therapeutic application.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (949K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Lorand L, Losowsky MS, Miloszewski KJ. Human factor XIII: fibrin-stabilizing factor. Prog Hemost Thromb. 1980;5:245–290. [PubMed]
  • Roberts WW, Lorand L, Mockros LF. Viscoelastic properties of fibrin clots. Biorheology. 1973 Mar;10(1):29–42. [PubMed]
  • Gerth C, Roberts WW, Ferry JD. Rheology of fibrin clots. II. Linear viscoelastic behavior in shear creep. Biophys Chem. 1974 Oct;2(3):208–217. [PubMed]
  • Shen LL, McDonagh RP, McDonagh J, Hermans J., Jr Fibrin gel structure: influence of calcium and covalent cross-linking on the elasticity. Biochem Biophys Res Commun. 1974 Feb 4;56(3):793–798. [PubMed]
  • Shen LL, Hermans J, McDonagh J, McDonagh RP, Carr M. Effects of calcium ion and covalent crosslinking on formation and elasticity of fibrin cells. Thromb Res. 1975 Mar;6(3):255–265. [PubMed]
  • Nelb GW, Gerth C, Ferry JD. Rheology of fibrin clots. III. Shear creep and creep recovery of fine ligated and coarse unligated closts. Biophys Chem. 1976 Sep;5(3):377–387. [PubMed]
  • Lorand L, Rule NG, Ong HH, Furlanetto R, Jacobsen A, Downey J, Oner N, Bruner-Lorand J. Amine specificity in transpeptidation. Inhibition of fibrin cross-linking. Biochemistry. 1968 Mar;7(3):1214–1223. [PubMed]
  • Mockros LF, Roberts WW, Lorand L. Viscoelastic properties of ligation-inhibited fibrin clots. Biophys Chem. 1974 Aug;2(2):164–169. [PubMed]
  • Glover CJ, McIntire LV, Brown CH, 3rd, Natelson EA. Rheological properties of fibrin clots. Effects of fibrinogen concentration, Factor XIII deficiency, and Factor XIII inhibition. J Lab Clin Med. 1975 Oct;86(4):644–656. [PubMed]
  • Curtis CG, Lorand L. Fibrin-stabilizing factor (factor XIII). Methods Enzymol. 1976;45:177–191. [PubMed]
  • Curtis CG, Brown KL, Credo RB, Domanik RA, Gray A, Stenberg P, Lorand L. Calcium-dependent unmasking of active center cysteine during activation of fibrin stabilizing factor. Biochemistry. 1974 Aug 27;13(18):3774–3780. [PubMed]
  • ASTRUP T, BRAKMAN P, NISSEN U. THE ESTIMATION OF FIBRINOGEN. A REVISION. Scand J Clin Lab Invest. 1965;17:57–65. [PubMed]
  • Carr ME, Shen LL, Hermans J. A physical standard of fibrinogen: measurement of the elastic modulus of dilute fibrin gels with a new elastometer. Anal Biochem. 1976 May 7;72:202–211. [PubMed]
  • Schwartz ML, Pizzo SV, Hill RL, McKee PA. Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem. 1973 Feb 25;248(4):1395–1407. [PubMed]
  • Lorand L, Ong HH. Labeling of amine-acceptor cross-linking sites of fibrin by transpeptidation. Biochemistry. 1966 May;5(5):1747–1753. [PubMed]
  • Lorand L, Parameswaran KN, Stenberg P, Tong YS, Velasco PT, Jönsson NA, Mikiver L, Moses P. Specificity of guinea pig liver transglutaminase for amine substrates. Biochemistry. 1979 May 1;18(9):1756–1765. [PubMed]
  • Lorand JB, Pilkington TR, Lorand L. Inhibitors of fibrin cross-linking: relevance for thrombolysis. Nature. 1966 Jun 18;210(5042):1273–1274. [PubMed]
  • Sakata Y, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest. 1980 Feb;65(2):290–297. [PMC free article] [PubMed]
  • Lorand L, Campbell-Wilkes LK, Cooperstein L. A filter paper assay for transamidating enzymes using radioactive amine substrates. Anal Biochem. 1972 Dec;50(2):623–631. [PubMed]
  • Lorand L, Lockridge OM, Campbell LK, Myhrman R, Bruner-Lorand J. Transamidating enzymes. II. A continuous fluorescent method suited for automating measurements of factor XIII in plasma. Anal Biochem. 1971 Nov;44(1):221–231. [PubMed]
  • Lorand L, Urayama T, De Kiewiet JW, Nossel HL. Diagnostic and genetic studies on fibrin-stabilizing factor with a new assay based on amine incorporation. J Clin Invest. 1969 Jun;48(6):1054–1064. [PMC free article] [PubMed]
  • Credo RB, Curtis CG, Lorand L. Alpha-chain domain of fibrinogen controls generation of fibrinoligase (coagulation factor XIIIa). Calcium ion regulatory aspects. Biochemistry. 1981 Jun 23;20(13):3770–3778. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...